- Avalo scores Phase 2 success in comeback bid, raises $375MAvalo Therapeutics’ comeback bid surged forward Tuesday afternoon, as the immunology biotech secured a mid-stage trial win in an inflammatory skin disorder. Avalo said that both doses of an exper…Endpoints · 2mo ago↗ source
- Avalo shares spike on skin drug data; BioNTech to cut staff<figure><div><img src="https://imgproxy.divecdn.com/idsdMAHsPbXObDUtQW2qRG7uveBUVv6HCTn9NTtlDOI/g:nowe:0:0/c:1207:682/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0x…BioPharma Dive · 2mo ago↗ source
- GSK goes to China for $1B siRNA deal in Arrowhead's obesity laneGSK is further delving into the cardiometabolic space — and deepening its relationship with China biotechs — in a $1 billion biobucks deal with an siRNA startup. The UK pharma is teaming with Suz…